The central concept emerging from the review is metabolic plasticity. Unlike many differentiated cancer cells that become locked into a single metabolic strategy, BCSCs can dynamically shift among glycolysis, the rapid but inefficient fermentation of glucose; oxidative phosphorylation, the mitochondrial process that extracts far more energy per glucose molecule; lipid metabolism, which supplies both fuel and membrane components; and amino acid metabolism, which feeds protein synthesis and redox balancing. This flexibility allows BCSCs to maintain their stem-like properties, including self-renewal and the capacity to regenerate an entire tumor, even as oxygen levels, nutrient availability, and signaling conditions fluctuate dramatically within a growing tumor.

Historically, cancer metabolism research was dominated by the Warburg effect, the observation that many tumors prefer glycolysis even in the presence of oxygen. The BCSC literature complicates that picture considerably. Studies cited in the review indicate that stem-like breast cancer cells often rely heavily on mitochondrial oxidative phosphorylation, particularly in populations enriched for markers such as ALDH activity, while more proliferative, non-stem tumor cells tend toward glycolysis. Other work has shown that under hypoxia, hypoxia-inducible factors drive glycolytic enzymes and stemness factors simultaneously, linking a low-oxygen niche directly to the maintenance of the stem-like state. The lesson is that no single metabolic fingerprint defines a BCSC; rather, the fingerprint changes with cellular state and environmental context, and that adaptability is itself a therapeutic problem.

Lipid metabolism has emerged as a particularly important pillar of BCSC biology. Fatty acid oxidation provides abundant ATP and NADPH, helping these cells resist oxidative stress, while de novo lipid synthesis supports membrane expansion during division and the generation of signaling lipids. Enzymes such as acetyl-CoA carboxylase and fatty acid synthase, along with uptake of exogenous fatty acids through CD36, have been implicated in stemness and metastatic potential in breast cancer models. The review emphasizes that lipid handling is not merely a fuel issue: lipid species can influence membrane fluidity, signaling cascades, and even the epigenetic marks that keep stemness programs active, tying metabolism directly to gene regulation.

Amino acid metabolism completes the picture. Glutamine, the most abundant circulating amino acid, feeds the tricarboxylic acid cycle through glutaminolysis, supplies nitrogen for nucleotide synthesis, and supports glutathione production for antioxidant defense. BCSCs, which must endure reactive oxygen species generated by chemotherapy and by their own metabolic activity, appear particularly dependent on such redox-buffering pathways. Serine, glycine, and branched-chain amino acid metabolism have also been linked to tumor initiation and progression in breast cancer, underscoring how the manipulation of nutrient streams beyond glucose shapes the fitness of the most dangerous cells in a tumor.

What elevates the review beyond a catalog of pathways is its insistence that BCSC metabolism cannot be understood in isolation. The tumor microenvironment is a metabolic ecosystem in which adipocytes, cancer-associated fibroblasts, endothelial cells, and immune cells all exchange nutrients and emit paracrine signals that reshape how cancer cells process fuel. In the breast, adipocytes are abundant and can release fatty acids and adipokines that tumor cells readily exploit. Fibroblasts can secrete lactate and alanine that neighboring cancer cells take up as carbon sources, a phenomenon sometimes described as metabolic symbiosis. Endothelial cells lining tumor vasculature influence oxygen and nutrient delivery, while immune cells both compete for nutrients and respond to metabolic signals that can dampen antitumor activity.

The relationship runs in both directions. The review highlights that BCSCs actively remodel their niche to favor tumor initiation, immune evasion, and metastatic colonization. By consuming key nutrients, secreting lactate and other metabolites, and altering extracellular matrix composition, BCSCs can condition their surroundings to suppress cytotoxic T cell function and recruit immunosuppressive cell types. Metabolites themselves act as signaling molecules: lactate, for example, is now recognized as an immunosuppressive oncometabolite, while lipid accumulation in the tumor microenvironment has been associated with dysfunction in antitumor immune cells. This metabolic crosstalk means that targeting BCSC metabolism may simultaneously disarm the protective niche those cells construct around themselves.

Metastasis represents perhaps the most dramatic test of metabolic plasticity. A cancer cell leaving a primary tumor must survive in circulation, endure shear stress and detachment-induced stress, and then colonize tissues with entirely different nutrient and oxygen landscapes, whether bone, lung, liver, or brain. The review discusses how BCSCs and cells with stem-like properties appear pre-adapted for this journey, in part because their flexible metabolism allows them to switch fuel sources as they encounter new microenvironments. At metastatic sites, interactions with resident stromal cells, including osteoclasts in bone or astrocytes in brain, can supply additional metabolic support, illustrating how niche-derived signals continue to govern BCSC behavior long after cells have left the primary tumor.

These insights are now informing therapeutic strategies. The review surveys approaches aimed at metabolic vulnerabilities, including inhibitors of mitochondrial complexes, fatty acid oxidation and synthesis blockers, glutaminase inhibitors, and agents targeting key regulators such as AMPK, mTOR, and hypoxia-inducible factors. Combination strategies that pair metabolic drugs with chemotherapy, endocrine therapy, or immunotherapy are of particular interest, since metabolic rewiring is one route by which BCSCs survive conventional treatment. The authors also acknowledge the challenges: metabolic redundancy means that blocking one pathway often pushes cells onto another, systemic toxicity is a real concern because normal stem cells and immune cells share many of these pathways, and the plasticity that makes BCSCs dangerous also makes them capable of adapting to single-agent metabolic therapies.

The broader message of the Lee and Kang review is that breast cancer should be viewed not just as a genetic disease but as a metabolic and ecological one, in which the fittest cells thrive by continuously renegotiating their relationship with available fuel and with their neighbors. Understanding the interconnected metabolic networks and niche-derived signals that govern BCSC behavior, the authors argue, may enable the development of more effective therapies designed to reduce breast cancer progression and recurrence. As open-access work, the review offers researchers and clinicians alike a comprehensive map of a field that is moving rapidly, and it makes a compelling case that the next generation of breast cancer treatments will need to target not only what cancer cells are, but what they eat, how they breathe, and the company they keep.

Subject of Research: Metabolic plasticity and microenvironmental regulation of breast cancer stem cells

Article Title: Breast cancer stem cell metabolism: metabolic plasticity and microenvironmental regulation

Article References: Lee, E., & Kang, Y. (2026). Breast cancer stem cell metabolism: metabolic plasticity and microenvironmental regulation. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-026-06435-3

Image Credits: AI Generated

DOI: 10.1007/s00018-026-06435-3

Keywords: breast cancer stem cells, metabolic plasticity, tumor microenvironment, glycolysis, oxidative phosphorylation, lipid metabolism, amino acid metabolism, metastasis, therapeutic resistance, immune evasion, cancer metabolism, tumor niche

Breast cancer stem cells, commonly called CSCs, represent a relatively small and adaptable population within a tumor. Unlike most rapidly dividing cancer cells, CSCs can self-renew, generate more differentiated tumor cells, and survive conditions that eliminate other malignant cells. These properties have been linked to recurrence, metastasis, and treatment failure. Although cancer metabolism has often been associated with increased glucose consumption and glycolysis, CSCs can also depend heavily on mitochondria, the organelles that generate ATP through oxidative phosphorylation. This reliance led the researchers to investigate POLG, the enzyme responsible for copying and repairing mitochondrial DNA.

POLG operates as a two-part molecular machine. The catalytic subunit is encoded by the POLG1 gene, while the accessory subunit is encoded by POLG2. Together, these proteins help replicate the small circular genome carried inside mitochondria. Mitochondrial DNA encodes essential components of the respiratory chain, the series of protein complexes that transfer electrons and use the released energy to produce ATP. If mitochondrial DNA is depleted or damaged, respiratory-chain assembly can fail, reducing energy production and altering the balance of reactive oxygen species inside the cell. The researchers therefore asked whether impairing POLG would interfere with the biology of breast cancer stem cells.

The experiments were initially performed in MCF-7 cells, an estrogen receptor-positive breast cancer model. Using genetic silencing, the investigators reduced expression of either POLG1 or POLG2. The effects on mitochondrial DNA were substantial: POLG1 silencing lowered mitochondrial DNA content by about 80%, while POLG2 silencing caused an approximately 70% reduction. These changes were accompanied by decreased levels of MTCO2, a protein encoded by mitochondrial DNA and required for respiratory-chain function. Measurements of mitochondrial membrane potential, respiration, and ATP production also indicated that the organelles were operating less efficiently after POLG disruption.

The mitochondrial defects were closely associated with a loss of stemness-related characteristics. In MCF-7 cells, silencing POLG1 reduced expression of OCT4, a transcription factor involved in maintaining cellular plasticity and self-renewal. The cells also formed roughly 70% fewer mammospheres, three-dimensional structures used as an in vitro indicator of mammary stem-cell activity. Their ability to generate colonies was markedly suppressed as well. Silencing POLG2 produced a similar pattern, reducing OCT4 expression, mammosphere formation, and clonogenic growth. Notably, these interventions did not substantially affect short-term growth in conventional two-dimensional cultures, suggesting that mitochondrial POLG activity may be particularly important for long-term self-renewal rather than immediate cell proliferation.

The study also examined how POLG disruption changed the chemical environment within mitochondria. Loss of mitochondrial membrane potential is a sign that the electrochemical gradient used to drive ATP synthesis has been weakened. At the same time, POLG1 and POLG2 silencing increased mitochondrial superoxide, a reactive oxygen species generated when electrons leak from the respiratory chain. This increase did not translate into a statistically significant rise in total cellular reactive oxygen species in every experiment, indicating that mitochondrial stress and whole-cell oxidative stress are not identical measurements. The results instead point to a localized disturbance in mitochondrial redox balance that may contribute to the loss of CSC-associated properties.

To test whether the genetic results could be reproduced with drugs, the researchers examined Alovudine, a nucleoside reverse transcriptase inhibitor developed for antiviral use. Alovudine can inhibit POLG as an off-target effect, although it is not a selective POLG-directed cancer drug. In the breast cancer cells, the compound reduced mammosphere and colony formation while lowering MTCO2 expression, mitochondrial respiration, and ATP generation. The authors emphasize that Alovudine caused hematological toxicities during antiviral development, making it unsuitable as an established cancer treatment on the basis of these experiments. Its role in the study was primarily to provide pharmacological support for the idea that POLG-dependent mitochondrial function is connected to cancer stemness.

The investigators then used a second compound, zalcitabine, also known as ddC, to determine whether the observations depended on a single drug. In MCF-7 cells, ddC impaired mitochondrial respiration, reduced MTCO2 levels, and suppressed both mammosphere and colony formation. The researchers extended the analysis to T47D, MDA-MB-231, MDA-MB-436, and MDA-MB-453 breast cancer cells, representing different biological subtypes and molecular characteristics. Across these models, ddC consistently reduced mammosphere formation, although its effects on ordinary monolayer growth varied. Non-tumoral MCF10A mammary epithelial cells showed limited viability changes under the tested conditions, a result that may indicate some degree of selectivity but cannot substitute for formal toxicity and therapeutic-index studies.

The molecular response to ddC also varied between cancer models. In MCF-7 cells, the compound markedly reduced the stemness-associated transcription factors SOX2 and NANOG. In MDA-MB-453 cells, SOX2 declined, whereas the effect on NANOG was more modest. Such differences are important because breast cancer is not a single disease: tumors differ in receptor status, genomic alterations, mitochondrial activity, and dependence on particular metabolic pathways. The researchers additionally analyzed clinical data from 458 patients with high-risk, estrogen receptor-positive, lymph node-positive luminal A breast cancer. Higher POLG1 expression was associated with poorer overall survival, with a hazard ratio of 1.34, and with shorter relapse-free, distant metastasis-free, and post-progression survival. These preliminary associations do not prove that POLG drives poor outcomes, and they require validation in independent patient cohorts using multivariable analyses.

The authors describe the work as a pilot study and stress that important questions remain unanswered. Much of the genetic evidence came from MCF-7 cells, and shRNA-based experiments can produce off-target effects that complicate interpretation. Neither Alovudine nor ddC is a fully selective POLG inhibitor, so their effects may involve additional molecular targets. The experiments were performed in cultured cells rather than animals or patients, meaning that the study does not yet demonstrate tumor suppression in a living organism or establish whether POLG inhibition can spare normal tissues. Future research will need to use independent genetic strategies, selective chemical probes, patient-derived models, xenografts, and orthotopic tumors. Nevertheless, the study identifies a compelling connection between mitochondrial DNA maintenance and breast cancer stem-cell behavior. By showing that POLG disruption can weaken mitochondrial respiration, alter redox balance, and suppress self-renewal across multiple models, the findings position POLG as a candidate biomarker and a possible target for therapies designed to attack the metabolically resilient cells that help breast tumors persist and return.

Subject of Research: Cells

Article Title: Investigating POLG-driven modulation of cancer stemness: a pilot study in breast cancer cells

News Publication Date: 24 August 2026

Web References: Aging, Volume 18; https://doi.org/10.18632/aging.206406; Aging-US

References: Chinigò et al., “Investigating POLG-driven modulation of cancer stemness: a pilot study in breast cancer cells,” Aging, DOI: 10.18632/aging.206406

Image Credits: Copyright © 2026 Chinigò et al.; Figure 2, distributed under the Creative Commons Attribution License (CC BY 4.0).

Keywords: breast cancer, cancer stem cells, cancer metabolism, POLG, POLG1, POLG2, mitochondrial DNA, mitochondrial function, oxidative phosphorylation, cancer stemness

Breast cancer treatment has long been challenged by the resilience of cancer stem cells, responsible for tumor initiation, metastasis, and relapse. These specialized cells exhibit remarkable adaptability, often evading conventional chemotherapy that targets rapidly proliferating cells. Paclitaxel operates by stabilizing microtubules, effectively halting mitosis, particularly at the G2/M phase transition, thereby preventing tumor growth. However, BCSCs frequently develop mechanisms to bypass this blockade, diminishing the drug’s impact. The newfound understanding of miR-181a-3p’s role adds a crucial layer to this complex dynamic.

MicroRNAs (miRNAs) are small, non-coding RNA molecules that regulate gene expression post-transcriptionally. Their involvement in cancer biology has emerged as a transformative field, illuminating pathways that govern cell proliferation, apoptosis, and differentiation. Specifically, miR-181a-3p has garnered interest due to its regulatory influence on cell cycle-related proteins. Researchers now demonstrate that inhibiting miR-181a-3p disrupts the regulatory network that allows BCSCs to escape paclitaxel-induced G2/M arrest, thereby sensitizing these cells to chemotherapy.

At a molecular level, the suppression of miR-181a-3p leads to the upregulation of key cell cycle inhibitors. These inhibitors are essential for maintaining the integrity of the G2/M checkpoint, ensuring cells do not proceed to mitosis with DNA damage or incomplete replication. When miR-181a-3p is active, it downregulates these inhibitors, facilitating unchecked progression through the cell cycle. The study elucidates how targeting this microRNA reinstates the natural failsafe mechanisms, amplifying paclitaxel’s efficacy.

This revelation carries profound implications for addressing chemoresistance. Resistance development is often attributed to genetic and epigenetic alterations within tumor cells, including BCSCs. By combining miR-181a-3p inhibition with paclitaxel treatment, there is enhanced control over the cell cycle arrest, making cancer cells more vulnerable to cytotoxic effects. This combinatorial approach could eventually lead to reduced drug dosages, minimizing side effects while maximizing therapeutic outcomes.

The methodology applied in this research entailed advanced molecular techniques, including RNA interference and cell cycle assays. Using breast cancer stem cell lines, investigators meticulously silenced miR-181a-3p and observed the subsequent molecular and phenotypic changes. Results consistently showed an increase in G2/M arrest markers upon miR-181a-3p inhibition when cells were treated with paclitaxel, affirming a synergistic relationship between the two treatments.

Moreover, in vivo studies using xenograft models provided critical validation. Mice implanted with BCSCs displayed significantly reduced tumor volumes when subjected to combined miR-181a-3p inhibition and paclitaxel treatment compared to controls. This preclinical evidence offers a compelling rationale for advancing this strategy into clinical trials, underscoring its translational potential.

This research not only augments our understanding of breast cancer biology but also exemplifies the emerging paradigm of targeting miRNAs as therapeutic adjuncts. As microRNA therapeutics evolve, the ability to fine-tune cancer cell signaling pathways with precise molecular interventions holds promise for increasing the specificity and efficacy of cancer treatment regimens.

The interplay identified between miR-181a-3p and the cell cycle checkpoint machinery also invites further investigation into how other microRNAs might influence chemotherapeutic responses. Elucidating these networks could enable the design of personalized medicine approaches, tailoring treatment to the genetic and epigenetic landscape of an individual’s tumor.

Another critical dimension lies in the potential for overcoming metastasis, often linked with the aggressive behavior of BCSCs. Ensuring that miR-181a-3p inhibitors can traverse biological barriers and reach the tumor microenvironment effectively will be pivotal for therapeutic success. Future research must address delivery mechanisms, dosage optimization, and long-term effects to translate these promising findings into clinical practice.

The findings also prompt reassessment of current breast cancer treatment protocols. Integrating miRNA-targeted therapies with existing chemotherapeutic agents might become the new standard, particularly for patients exhibiting resistance to conventional regimens. This approach aligns with the broader oncology trend of combination therapies devised to circumvent resistance mechanisms and improve survival rates.

In summary, the targeted defeat of miR-181a-3p represents a novel and promising strategy to potentiate paclitaxel’s ability to induce G2/M cell cycle arrest in breast cancer stem cells. By reinstating the checkpoint controls that cancer cells often evade, this approach offers renewed hope for tackling the persistent challenge of chemoresistance and tumor relapse. As research progresses, the clinical translation of these findings could radically enhance the management of breast cancer, offering patients more effective and durable treatments.

This innovative work stands at the intersection of molecular oncology, pharmacology, and stem cell biology, highlighting the power of integrating multidisciplinary insights to combat cancer. The study invites the scientific community to explore microRNA modulation as a frontier in cancer therapy, potentially revolutionizing how we understand, diagnose, and treat one of the leading causes of cancer mortality worldwide.

The prospect of using microRNA inhibitors such as anti-miR-181a-3p alongside paclitaxel opens a new chapter in precision oncology, where the molecular signature of cancer stem cells could dictate therapeutic choices. This strategy exemplifies the move from one-size-fits-all chemotherapy towards targeted interventions designed to exploit specific vulnerabilities within cancer cells.

As the fight against breast cancer continues, these findings provide a beacon of innovation, encouraging further exploration into the molecular underpinnings of cell cycle regulation. By harnessing the power of microRNA biology, researchers stand on the brink of delivering more effective, less toxic cancer treatments that promise longer survival and improved quality of life for patients worldwide.

Subject of Research: The role of miR-181a-3p inhibition in enhancing the effect of paclitaxel on inducing G2/M cell cycle arrest in breast cancer stem cells.

Article Title: Defeating miR-181a-3p may potentiate the effect of paclitaxel on G2/M arrest in breast cancer stem cells.

Article References:
Asik, A., Goker Bagca, B., Ozates, N.P. et al. Defeating miR-181a-3p may potentiate the effect of paclitaxel on G2/M arrest in breast cancer stem cells. Med Oncol 42, 538 (2025). https://doi.org/10.1007/s12032-025-03111-7

Image Credits: AI Generated

DOI: https://doi.org/10.1007/s12032-025-03111-7